Cargando…

Enhancing glioblastoma treatment through the integration of tumor-treating fields

Glioblastoma (GBM) represents a significant therapeutic challenge due to its aggressive nature. Tumor Treating Fields (TTFields) present a promising approach to GBM therapy. The primary mechanism of TTFields, an antimitotic effect, alongside numerous indirect effects including increased cell membran...

Descripción completa

Detalles Bibliográficos
Autores principales: Szklener, Katarzyna, Bilski, Mateusz, Nieoczym, Karolina, Mańdziuk, Dominika, Mańdziuk, Sławomir
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10616854/
https://www.ncbi.nlm.nih.gov/pubmed/37916157
http://dx.doi.org/10.3389/fonc.2023.1274587
_version_ 1785129484983205888
author Szklener, Katarzyna
Bilski, Mateusz
Nieoczym, Karolina
Mańdziuk, Dominika
Mańdziuk, Sławomir
author_facet Szklener, Katarzyna
Bilski, Mateusz
Nieoczym, Karolina
Mańdziuk, Dominika
Mańdziuk, Sławomir
author_sort Szklener, Katarzyna
collection PubMed
description Glioblastoma (GBM) represents a significant therapeutic challenge due to its aggressive nature. Tumor Treating Fields (TTFields) present a promising approach to GBM therapy. The primary mechanism of TTFields, an antimitotic effect, alongside numerous indirect effects including increased cell membrane permeability, signifies their potential in combination with other treatment modalities. Current combinations often include chemotherapy, particularly with temozolomide (TMZ), however, emerging data suggests potential synergy with targeted therapies, radiotherapy, and immunotherapy as well. TTFields display minimal side effects, predominantly skin-related, posing no significant barrier to combined therapies. The effectiveness of TTFields in GBM treatment has been demonstrated through several post-registration studies, advocating for continued research to optimize overall survival (OS) and progression-free survival (PFS) in patients, as opposed to focusing solely on quality of life.
format Online
Article
Text
id pubmed-10616854
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-106168542023-11-01 Enhancing glioblastoma treatment through the integration of tumor-treating fields Szklener, Katarzyna Bilski, Mateusz Nieoczym, Karolina Mańdziuk, Dominika Mańdziuk, Sławomir Front Oncol Oncology Glioblastoma (GBM) represents a significant therapeutic challenge due to its aggressive nature. Tumor Treating Fields (TTFields) present a promising approach to GBM therapy. The primary mechanism of TTFields, an antimitotic effect, alongside numerous indirect effects including increased cell membrane permeability, signifies their potential in combination with other treatment modalities. Current combinations often include chemotherapy, particularly with temozolomide (TMZ), however, emerging data suggests potential synergy with targeted therapies, radiotherapy, and immunotherapy as well. TTFields display minimal side effects, predominantly skin-related, posing no significant barrier to combined therapies. The effectiveness of TTFields in GBM treatment has been demonstrated through several post-registration studies, advocating for continued research to optimize overall survival (OS) and progression-free survival (PFS) in patients, as opposed to focusing solely on quality of life. Frontiers Media S.A. 2023-10-17 /pmc/articles/PMC10616854/ /pubmed/37916157 http://dx.doi.org/10.3389/fonc.2023.1274587 Text en Copyright © 2023 Szklener, Bilski, Nieoczym, Mańdziuk and Mańdziuk https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Szklener, Katarzyna
Bilski, Mateusz
Nieoczym, Karolina
Mańdziuk, Dominika
Mańdziuk, Sławomir
Enhancing glioblastoma treatment through the integration of tumor-treating fields
title Enhancing glioblastoma treatment through the integration of tumor-treating fields
title_full Enhancing glioblastoma treatment through the integration of tumor-treating fields
title_fullStr Enhancing glioblastoma treatment through the integration of tumor-treating fields
title_full_unstemmed Enhancing glioblastoma treatment through the integration of tumor-treating fields
title_short Enhancing glioblastoma treatment through the integration of tumor-treating fields
title_sort enhancing glioblastoma treatment through the integration of tumor-treating fields
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10616854/
https://www.ncbi.nlm.nih.gov/pubmed/37916157
http://dx.doi.org/10.3389/fonc.2023.1274587
work_keys_str_mv AT szklenerkatarzyna enhancingglioblastomatreatmentthroughtheintegrationoftumortreatingfields
AT bilskimateusz enhancingglioblastomatreatmentthroughtheintegrationoftumortreatingfields
AT nieoczymkarolina enhancingglioblastomatreatmentthroughtheintegrationoftumortreatingfields
AT mandziukdominika enhancingglioblastomatreatmentthroughtheintegrationoftumortreatingfields
AT mandziuksławomir enhancingglioblastomatreatmentthroughtheintegrationoftumortreatingfields